Semaglutide is an ingredient name, not one universal online product. Wegovy is an approved branded medicine, while some providers advertise compounded preparations using semaglutide. These pathways differ in product status and should not be merged simply because a headline uses the same ingredient.
The entries below cover a published compounded offer, clinical membership models, and official branded information. A clinician should assess the actual product and the reader’s medical history. Use the review to learn what to confirm, then discuss the prescription before enrollment.
Semaglutide $948/year ($79/mo equivalent) or $139 month-to-month; tirzepatide terms differ
Likeness Rx offers compounded semaglutide and tirzepatide with explicit term pricing. Its lowest advertised monthly equivalents are $79 and $129 on annual prepaid terms; month-to-month options cost more.
Wegovy is a branded semaglutide medicine record, not a clinic; its current forms, indications and savings terms must remain distinct from a provider’s package.
Confirm the exact preparation, renewal, supplied amount, pharmacy, and clinical follow-up for the chosen order.
The details, visualized
Semaglutide evidence anchor: STEP 1
Mean reduction from baseline body weight (%)
Semaglutide 2.4 mg14.9%
Mean percentage reduction in the randomized treatment group.
Placebo2.4%
Both groups also received lifestyle intervention.
Group averages, not individual predictions. Doses identify trial arms, not dosing advice. These data do not establish outcomes for compounded preparations. Bars start at zero.
STEP 1 gives an evidence anchor for a specific once-weekly semaglutide regimen in adults without diabetes. It does not measure the service quality of the online providers in this list or validate an unspecified compounded vial. The medicine’s route, formulation and approved indication must remain attached to any research claim.
For the purchasing comparison, ask whether the quote describes branded access or a compounded preparation, what the clinician’s rationale is, and what instructions accompany the supplied product. A shared ingredient name is not enough to reuse another provider’s concentration or administration instructions.
Before you decide
Questions worth answering
Does the order on this page identify the best treatment for me?
No. It is a publisher-arranged comparison of selected public offers. The chart explains the specific purchase or evidence question; a licensed clinician must assess the actual treatment.
What should I verify for this comparison?
Semaglutide evidence belongs to the studied product and regimen. Offer prices do not establish equivalent preparations. Ask for the selected written quote and the product-specific clinical explanation before making a purchase.
Evidence behind this page
Sources & chart notes
Checked October 7, 2026. Provider pages establish advertised terms. Labels and trial reports describe specific medicines and study populations. Medical review has not been completed.
Semaglutide Injection Offers — keep the exact product identity and its complete label together.
An approved product has its own information
Use the official Wegovy information for its indications and safety discussion. Clinical results are not promises for an individual, and they do not establish the performance of an unspecified compounded preparation. Read the Wegovy product profile for the source links.
An approved product has its own information — keep the exact product identity and its complete label together.
A compounded offer needs an individual rationale
Ask why an approved medicine cannot meet your needs and which pharmacy supplies the preparation. Confirm the formulation and written directions. The product-status guide explains why a compounded product is not an FDA-approved generic.
Membership is not always the medicine price
A low care fee can leave the pharmacy expense separate. Match the product, supplied quantity, and normal renewal with the membership charges. The invoice worksheet turns those different figures into a useful comparison.